Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules Yuichi Kobayashi Editor

Total Page:16

File Type:pdf, Size:1020Kb

Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules Yuichi Kobayashi Editor Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules Yuichi Kobayashi Editor Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules The Shape of Organic Synthesis to Come Editor Yuichi Kobayashi Department of Biotechnology Tokyo Institute of Technology Yokohama, Japan ISBN 978-981-13-6243-9 ISBN 978-981-13-6244-6 (eBook) https://doi.org/10.1007/978-981-13-6244-6 © Springer Nature Singapore Pte Ltd. 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore Preface The purpose of organic synthesis is to provide target compounds by selective meth- ods with high optical purity. Many transition metal-catalyzed asymmetric reactions and reactions catalyzed by organocatalysts have been developed to efficiently reach the goals. Reducing and oxidizing reagents that are highly chemoselective and/or environmentally friendly are also indispensable tools toward the purpose. On the other hand, analytical techniques have advanced to allow swift determination of the efficiency of reactions and the structures. For example, LC-MS analysis equipped with a chiral column could determine the chirality of the structure. Such new reac- tions and the advances in analytical techniques produced new power for organic synthesis to foray into fields, which used to be considered out of organic synthesis. As a consequence, many interdisciplinary areas have emerged, attracted attention of chemists, and rapidly grown. This book was planned to grasp the latest and excellent achievements in organic synthesis, which are expected to be grown more in the future. On the other hand, the background of each chapter is explained. I hope that the chapters will be understood easily by researchers, especially young, and stimulate research in the future. Chapters “Microbial Fraction Library: A Screening Source for Drug Discovery”, “Efficient Total Synthesis ofŌ mura Natural Products”, “Enantioselective Total Synthesis of the Antitumor Polycyclic Natural Products FR182877 and Taxol”, “Synthetic Approaches on the Pluramycin-Class Antibiotics”, “Recent Progress Toward the Total Synthesis of Duocarmycins A and SA, Yatakemycin, and PDE-I and –II”, “Structure-Activity Relationship Studies of Maitotoxin Based on Chemical Synthesis”, “Substitution of Allylic Picolinates with Various Copper Reagents and Synthetic Applications”, “Total Synthesis of Ingenol” present isolation, elucidation, and organic syntheses of several compounds that are naturally occurring. Organic synthesis and biosynthesis of metabolites of polyunsaturated fatty acids are described in chapters “Strategies for the Synthesis of Anti-inflammatory Metabolites of Unsaturated Fatty Acids” and “Biosynthesis, Biological Functions, and Receptors of Leukotriene B4 and 12(S)-Hydroxyheptadecatrienoic Acid”, respectively. Chapter “Synthesis of Classical/Nonclassical Hybrid Cannabinoids and Related Compounds” deals with natural and unnatural cannabinoids and would be helpful to design new v vi Preface medical cannabinoids. Chapters “Exploring Bioactive Marine Natural Products and Identification of Their Molecular Targets”, “Target Protein Chemical Modification”, “Target Identification of Bioactive Compounds by Photoaffinity Labeling Using Diazido Probes” explain chemical biology focusing on tools that are designed based on organic reaction and/or interaction with target proteins. The project of publishing this book began with an invitation of Mr. S. Koizumi, Springer Japan. I sincerely acknowledge Ms. A. Komada of Springer and Ms. M. Shimoda in our laboratory for checking the chapters carefully. Yokohama, Japan Yuichi Kobayashi Contents 1 Microbial Fraction Library: A Screening Source for Drug Discovery �������������������������������������������������������������������������������������������������� 1 Toshihiko Nogawa, Julius Adam V. Lopez, and Hiroyuki Osada 2 Efficient Total Synthesis of Ōmura Natural Products �������������������������� 21 Toshiaki Sunazuka, Tomoyasu Hirose, and Satoshi Ōmura 3 Enantioselective Total Synthesis of the Antitumor Polycyclic Natural Products FR182877 and Taxol �������������������������������������������������� 49 Masahisa Nakada 4 Synthetic Approaches on the Pluramycin-­Class Antibiotics ���������������� 75 Yoshio Ando, Kei Kitamura, Takashi Matsumoto, and Keisuke Suzuki 5 Recent Progress on the Total Synthesis of Duocarmycins A and SA, Yatakemycin, and PDE-I and PDE-II ������������������������������������������������������������������������������������������������ 101 Juri Sakata and Hidetoshi Tokuyama 6 Structure-Activity Relationship Studies of Maitotoxin Based on Chemical Synthesis ���������������������������������������������������������������������������� 125 Tohru Oishi 7 Substitution of Allylic Picolinates with Various Copper Reagents and Synthetic Applications ���������������������������������������������������� 145 Yuichi Kobayashi and Miwa Shimoda 8 Total Synthesis of Ingenol ������������������������������������������������������������������������ 171 Tyler F. Higgins and Jeffrey D. Winkler 9 Strategies for the Synthesis of Anti-­inflammatory Metabolites of Unsaturated Fatty Acids ��������������������������������������������������������������������� 193 Yuichi Kobayashi and Masao Morita vii viii Contents 10 Biosynthesis, Biological Functions, and Receptors of Leukotriene B4 and 12(S)-Hydroxyheptadecatrienoic Acid ������������ 233 Toshiaki Okuno and Takehiko Yokomizo 11 Synthesis of Classical/Nonclassical Hybrid Cannabinoids and Related Compounds ������������������������������������������������������������������������ 247 Thanh C. Ho and Marcus A. Tius 12 Exploring Bioactive Marine Natural Products and Identification of Their Molecular Targets �������������������������������������� 291 Masayoshi Arai 13 Target Protein Chemical Modification �������������������������������������������������� 305 Hiroyuki Nakamura 14 Target Identification of Bioactive Compounds by Photoaffinity Labeling Using Diazido Probes ���������������������������������� 335 Suguru Yoshida and Takamitsu Hosoya List of Figures Fig. 1.1 Screening strategy of interesting secondary metabolites................. 2 Fig. 1.2 Morphological profiles of HeLa and srcts-NRK cancer cells treated with pyrrolizilactone.................................................... 5 Fig. 1.3 Concept of the fraction library......................................................... 7 Fig. 1.4 Culture condition and preparation of crude extracts and fractions....................................................................... 8 Fig. 1.5 A basic concept of 2D separation for the preparation of fractions....................................................................................... 9 Fig. 1.6 Mass distribution of fractions.......................................................... 9 Fig. 1.7 General activity profile of the fraction library evaluated at 100 μg/mL.................................................................................... 10 Fig. 1.8 NPPlots and unusual alignments...................................................... 11 Fig. 1.9 NPPlots and specific metabolite group of Streptomyces sp. RK88–1355...................................................................................... 11 Fig. 1.10 Structure and putative biosynthetic pathway of verticilactam......... 12 Fig. 1.11 Structures and putative biosynthetic pathway of spirotoamides...... 13 Fig. 1.12 Structures of octaminomycins A and B........................................... 14 Fig. 1.13 NPPlot of Streptomyces sp. RK88–1355 and new antimycin-related metabolites.......................................................... 15 Fig. 1.14 Structural diversity of the antimycin class of metabolites............... 16 Fig. 1.15 Variety of the functional group at C-3 position............................... 17 Fig. 2.1 Our strategy...................................................................................... 22 Fig. 2.2 Structures of novel Ōmura natural products.................................... 23 Fig. 2.3 Structures of pyripyropenes............................................................. 24 Fig. 2.4 Biosynthesis of pyripyropene A......................................................
Recommended publications
  • Régulation De L'inflammation Par Les Lipides Bioactifs : Interactions Biosynthétiques Et Fonctionnelles Entre Les Endocannabinoïdes Et Les Éicosanoïdes
    Régulation de l'inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Doctorat en microbiologie-immunologie Philosophiæ doctor (Ph. D.) Québec, Canada © Caroline Turcotte, 2019 Régulation de l’inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Sous la direction de : Nicolas Flamand, directeur de recherche Marie-Renée Blanchet, codirectrice de recherche Résumé Les maladies inflammatoires chroniques sont un fardeau de santé important à travers le monde. Les traitements actuellement disponibles soulagent la douleur et l’inflammation, mais leurs effets secondaires rendent leur utilisation à long terme risquée. À la lumière de cette problématique, la communauté scientifique s’intéresse au potentiel d’anti-inflammatoires naturels comme les endocannabinoïdes. Les endocannabinoïdes sont des lipides endogènes qui activent les récepteurs cannabinoïdes (CB1 et CB2). Ils régulent ainsi divers processus physiologiques tels l’appétit, l’adipogénèse et la nociception. Les deux endocannabinoïdes les mieux caractérisés, le 2-AG et l’AEA, peuvent également moduler l’inflammation en activant le récepteur CB2 à la surface des cellules immunitaires. Les souris déficientes pour le récepteur CB2 présentent un phénotype inflammatoire exacerbé, suggérant que ce récepteur est anti-inflammatoire. Cependant, le rôle des endocannabinoïdes dans l’inflammation est beaucoup plus complexe puisqu’ils peuvent être métabolisés en une grande variété de médiateurs lipidiques de l’inflammation. Leur voie de dégradation principale est leur hydrolyse en acide arachidonique (AA), qui sert de précurseur à la biosynthèse d’éicosanoïdes pro-inflammatoires comme le leucotriène B4 et la prostaglandine E2. Ils peuvent également être métabolisés directement par certaines enzymes impliquées dans la synthèse d’éicosanoïdes, pour générer des médiateurs comme les prostaglandines-glycérol (PG-G).
    [Show full text]
  • Regulation of Brain Reward by the Endocannabinoid System: a Critical Review of Behavioral Studies in Animals
    Send Orders for Reprints to [email protected] Current Pharmaceutical Design, 2014, 20, 000-000 1 Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals S. Vlachou2 and G. Panagis1,* 1Laboratory of Behavioral Neuroscience, Department of Psychology, School of Social Sciences, University of Crete, 74100 Rethym- non, Crete, Greece; 2School of Nursing and Human Sciences, Faculty of Science and Health, Dublin City University, Glasnevin, Dub- lin 9, Ireland Abstract: The endocannabinoid system has been implicated in the regulation of a variety of physiological processes, including a crucial involvement in brain reward systems and the regulation of motivational processes. Behavioral studies have shown that cannabinoid re- ward may involve the same brain circuits and similar brain mechanisms with other drugs of abuse, such as nicotine, cocaine, alcohol and heroin, as well as natural rewards, such as food, water and sucrose, although the conditions under which cannabinoids exert their reward- ing effects may be more limited. The purpose of the present review is to briefly describe and evaluate the behavioral and pharmacological research concerning the major components of the endocannabinoid system and reward processes. Special emphasis is placed on data re- ceived from four procedures used to test the effects of the endocannabinoid system on brain reward in animals; namely, the intracranial self-stimulation paradigm, the self-administration procedure, the conditioned place preference procedure and the drug-discrimination pro- cedure. The effects of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor agonists, antagonists and endocannabinoid modulators in these procedures are examined. Further, the involvement of CB1 and CB2 receptors, as well the fatty acid amid hydrolase (FAAH) en- zyme in reward processes is investigated through presentation of respective genetic ablation studies in mice.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57bl/6J Mice
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2013 Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57Bl/6J Mice Jason Wiebelhaus Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Psychology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/555 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Jason Michael Wiebelhaus, 2013 All Rights Reserved Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57Bl/6J Mice Dissertation to be submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University By: Jason M. Wiebelhaus Master of Science, Virginia Commonwealth University, 2009 Bachelor of Science, University of WI-Eau Claire, 2006 Co-Directors: Aron H. Lichtman1, Ph.D. and Joseph H. Porter2, Ph.D. 1, 2Professors 1Department of Pharmacology and Toxicology, 2Department of Psychology Virginia Commonwealth University Richmond, VA September, 2013 ii Acknowledgement I owe my thanks to many people who helped me throughout the process of conducting these experiments and writing my dissertation. First and foremost I would like to thank my mentor and dissertation co-director director Aron H. Lichtman for his guidance and patience throughout my years of graduate school at Virginia Commonwealth University. I would also like to thank my committee members Joseph H.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-AROMOLINE 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 4 (+)-CEPHARANTHINE 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 2 (+)-ISOLARICIRESINOL 1 (+)-NORTRACHELOGENIN 1 (+)-PRAERUPTORUM-A 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (+)-TENUIPINE 1 (+)-TETRANDRINE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 1 (-)-APOGLAZIOVINE 2 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANADINE 1 (-)-CURINE 1 Chemical Activity Count (-)-DAURISOLINE 1 (-)-DICENTRINE 1 (-)-EMETINE 1 (-)-EPICATECHIN 3 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 2 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 2 (-)-EUDESMIN 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-IBOGAMINE 1 (-)-STEPHOLIDINE 1 (-)-TENUIPINE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 2 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 1-ETHYL-BETA-CARBOLINE 2 1-HYDROXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-METHOXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10,6-HONOKIOL 1
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Epilepsy
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Epilepsy Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 3 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-HERNANDEZINE 1 (+)-ISOCORYDINE 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 2 (-)-ANABASINE 1 (-)-APOGLAZIOVINE 1 (-)-BETONICINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-DICENTRINE 2 (-)-EPIAFZELECHIN 1 (-)-EPICATECHIN 1 (-)-EPIGALLOCATECHIN-GALLATE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (15:1)-CARDANOL 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 Chemical Activity Count 10-DEHYDROGINGERDIONE 1 10-GINGERDIONE 1 11-HYDROXY-DELTA-8-THC 1 11-HYDROXY-DELTA-9-THC 1 13',II8-BIAPIGENIN 1 13-OXYINGENOL-ESTER 1 16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 16-EPIMETHUENINE 1 16-HYDROXYINGENOL-ESTER 1 2'-O-GLYCOSYLVITEXIN 1 2-BETA,3BETA-27-TRIHYDROXYOLEAN-12-ENE-23,28-DICARBOXYLIC-ACID 1 2-METHYLBUT-3-ENE-2-OL 2 20-DEOXYINGENOL-ESTER 1 22BETA-ESCIN 1 24-METHYLENE-CYCLOARTANOL 1 3,3'-DIMETHYLELLAGIC-ACID 1 3,4-DIMETHOXYTOLUENE 1 3,4-METHYLENE-DIOXYCINNAMIC-ACID-BORNYL-ESTER 2 3,4-SECOTRITERPENE-ACID-20-EPI-KOETJAPIC-ACID 1 3-ACETYLACONITINE 1 3-ACETYLNERBOWDINE 1 3-BETA-HYDROXY-2,3-DIHYDROWITHANOLIDE-F 1 3-HYDROXY-FLAVONE 1 3-N-BUTYL-PHTHALIDE 3 3-O-ACETYLOLEANOLIC-ACID 1 3-OXO-11-ALPHA-HYDROXYOLEAN-12-ENE-30-OIC-ACID
    [Show full text]
  • Analysis of Bio-Molecules for System Level Understanding of Alzheimer’S Disease
    ANALYSIS OF BIO-MOLECULES FOR SYSTEM LEVEL UNDERSTANDING OF ALZHEIMER’S DISEASE By PRIYA PRADAYANI PANIGRAHI A THESIS SUBMITTED IN FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOINFORMATICS JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY WAKNAGHAT OCTOBER, 2014 ACKNOWLEDGEMENTS God gives blessings to us so we can give glory to him. I'm blessed and I thank God for everything in my life. I deem it my privilege and honour to place and record my gratitude and indebtedness to the following without whose support, guidance, and concern I would not have been able to complete my Ph. D thesis. I feel privileged to express my deep sense of reverence and gratitude to my revered mentor, Dr. Tiratha Raj Singh, for his support, immaculate guidance, constructive criticism, constant encouragement and providing requisite facilities to carry on my research which otherwise would have remained incomplete. His nurturing and caring concern has been a stimulus which I will always cherish. I also appreciate his untiring efforts during the entire tenure of my research work and patience during writing of this thesis. I have no words to express my gratitude for everything he has contributed in my Ph. D and without his blessings it was surely impossible for me to finish my work. I thank him from bottom of my heart. I emphatically express my loyal and venerable thanks to Prof. Shiban Kishen Kak (Vice Chancellor, JUIT), Brig. (Retd.) Balbir Singh (Director, JUIT), Prof. T. S.Lamba (Dean, JUIT) and Dr. Y. Medury (Ex-COO, Jaypee Education System) for providing opportunity to pursue a Doctorate Degree, teaching assistantship and advanced lab infrastructure to accomplish this scientific venture of my life.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for GERD / Esophageal Reflux
    Dr.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]